IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4184
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$88M
Dirk Thye
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$QNCX Quince Therapeutics, Inc. | 34 | 16 | 37 | 44 | - | - | -4719.4% | -45.5% | - | - | - | - | 0.0% | 0.0x | $88M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Quince Therapeutics, Inc. (QNCX) receives a "Avoid" rating with a composite score of 34.3/100. It ranks #4184 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
In-line with peers — no strong momentum signal
Fair valuation relative to peers
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for QNCX.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 16 | 1 | +15ALPHA |
| MOMENTUM | 44 | 35 | +9ALPHA |
| VALUATION | 37 | 26 | +11ALPHA |
| INVESTMENT | 25 | 13 | +12ALPHA |
| STABILITY | 27 | 11 | +16ALPHA |
| SHORT INT | 88 | 97 | -9DRAG |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -4719.4% (sector -1.9%)
GM N/A vs sector 44%, OM N/A vs sector 3%
Capital turnover N/A
Rev growth N/A, 7yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Quince Therapeutics, Inc. (QNCX) as Avoid with a composite score of 34.3/100 at a current price of $0.14. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
Quince Therapeutics, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 34.3/100 places it at rank #4184 in our full universe.
No Moat
Medium
Poor
Fair Value
Stable competitive position in a defensive sector.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
Quince Therapeutics, Inc. represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags Quince Therapeutics, Inc. with an Avoid rating, assigning a composite score of 34.3/100 and 1 out of 5 stars. Ranked #4184 of 7,333 stocks, QNCX falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
Quince Therapeutics, Inc. registers a weak quality score of just 16/100, indicating significant profitability challenges. The company reports a return on equity of -4719.4% (sector avg: -1.9%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
With a value score of 37/100, QNCX appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 7.20x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
Quince Therapeutics, Inc.'s investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -45.5% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
QNCX is currently showing below-average momentum at 44/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth data is not currently available, while a beta of 0.41 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
QNCX's stability score of 27/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 0.41 and a debt-to-equity ratio of 0.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
QNCX's short interest factor score of 88/100 indicates very low short selling activity relative to peers — a positive signal suggesting institutional investors see limited near-term downside. Specific risk factors include micro-cap liquidity risk. As a micro-cap company with a market capitalization of $88M, Quince Therapeutics, Inc. benefits from the generally lower volatility and deeper liquidity associated with its size class.
Quince Therapeutics, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4184 of 7,333 overall (43rd percentile). Key comparisons include ROE of -4719.4% trailing the -1.9% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While QNCX currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Quality (16) would have the largest impact on the composite score.
ROE 248292% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 100% BELOW SECTOR MEDIAN (FAVORABLE)
Div. Yield NaN% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
SOUTH SAN FRANCISCO, Calif., February 09, 2026--Quince Therapeutics, Inc. (Nasdaq: QNCX), today announced that it has engaged LifeSci Capital to serve as its exclusive financial advisor to assist in its restructuring and evaluation of strategic alternatives aimed at maximizing shareholder value.
SOUTH SAN FRANCISCO, Calif., January 29, 2026--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced topline results from its pivotal Phase 3 NEAT clinical trial evaluating its lead asset, dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP), in patients with Ataxia-Telangiectasia (A-T).
Gainers RVL Pharmaceuticals plc (NASDAQ: RVLP) shares rose 181.8% to $0.2201 in pre-market trading. Novo Integrated Sciences, Inc. (NASDAQ: NVOS) shares rose 86% to $0.3739 in pre-market trading. Novo Integrated Sciences and Blacksheep Trust signed a One Billion Dollar Master Collateral Transfer Agreement for the purpose and general use of monetization by Novo for a period of up to 15 years. Polished.com Inc. (NYSE: POL) shares surged 35% to $0.1060 in pre-market trading. Polished.com plans to hold a special meeting of stockholders to approve reverse stock split. OpGen, Inc. (NASDAQ: OPGN) shares gained 34.3% to $0.27 in pre-market trading. Brooge Energy Limited (NASDAQ: BROG) shares rose 23% to $6.64 in pre-market trading after gaining 7% on Thursday. iSun, Inc. (NASDAQ: ISUN) gained 18.3% to $0.2550 in pre-market trading. iSun recently filed for offering of up to 10.96 million shares of common stock by the selling stockholders. T2 Biosystems, Inc. (NASDAQ: TTOO) rose 17.2% to $0.2090 in pre-market trading. OPKO Health, Inc. (NASDAQ: OPK) shares ...
Gainers U.S. Xpress Enterprises, Inc. (NYSE: USX) shares surged 298% to $5.97 after Knight-Swift Transportation agreed to acquire the company for $6.15 per share. Impac Mortgage Holdings, Inc. (NYSE: IMH) gained 94.8% to $0.39. Impac Mortgage Holdings recently posted a Q4 adjusted loss of $0.35 per share. Cerberus Cyber Sentinel Corporation (NASDAQ: CISO) shares jumped 84.6% to $0.4245. Cerberus Cyber Sentinel said it sees Q4 revenue of $14.7 million and sees FY22 revenue of $46.5 million. Quince Therapeutics, Inc. (NASDAQ: QNCX) gained 74.7% to $1.4708 after Echo Lake Capital offered to acquire the company for $1.60 per share in cash. Pear Therapeutics, Inc.. (NASDAQ: PEAR) climbed 39.3% to $0.2919 after dropping 46% on Monday. Pear Therapeutics, last week, said it is exploring strategic alternatives and said it may seek a reorganization if it is unable to complete a transaction. First Republic Bank (NYSE: FRC) shares climbed 29.7% to $15.80 following reports suggesting JP Morgan CEO Jamie Dimon is leading discussions to come up with a new rescue plan for the bank. Also, Treasury Secretary Yellen said the government is prepared to take more action to aid banks, which could be positively impacting the stock. On Holding AG (NYSE: ONON) gained 29.1% to $27.85 after the company reported fourth-quarter FY22 sales growth of 91.9% year-on-year to CHF 366.8 million. Novo Integrated Sciences, Inc. (NASDAQ: NVOS) jumped 23.7% to $0.1255. Torrid Holdings Inc. (NYSE: CURV) surged 22.8% to $2.7385. EZGO Technologies Ltd. (NASDAQ: EZGO) jumped 22% to $1.23. Blue Star Foods Corp. (NASDAQ: BSFC) rose 21.6% to $0.1930. So-Young International Inc. (NASDAQ: SY) gained 20.6% to $1.99 following Q4 results. ImmunityBio, Inc. (NASDAQ: IBRX) gained 20% to $1.62. Novo ...
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Tuesday. The Dow traded up 0.41% to 32,376.61 while the NASDAQ rose 1.05% to 11,798.39. The S&P 500, also rose, gaining, 0.76% to 3,981.58. Check This Out: Meta Platforms To Rally Over 26%? Here Are 10 Other Analyst Forecasts For Tuesday Leading and Lagging Sectors Energy shares rose by 3.2% on Tuesday. Meanwhile, top gainers in the sector included Select Energy Services, Inc. (NYSE: WTTR), up 14%, and Hammerhead Energy Inc. (NASDAQ: HHRS), up 14%. In trading on Tuesday, utilities shares fell 2.9%. Top Headline Existing home sales in the US surged 14.5% to an annual rate of 4.58 million in February, compared to market estimates of a 5% growth. Equities Trading UP Quince Therapeutics, Inc. (NASDAQ: QNCX) shares shot up 71% to $1.4350 after Echo Lake Capital offered to acquire the company for $1.60 per share in cash. Shares of Cerberus Cyber Sentinel Corporation (NASDAQ: CISO) got a boost, shooting 65% to $0.3799. Cerberus Cyber Sentinel said it sees Q4 revenue of $14.7 million and sees FY22 revenue of $46.5 million. CISO proposed using the offering proceeds and ...